Preview: Actuate Therapeutics, Inc Set To IPO Tomorrow
Portfolio Pulse from Benzinga Insights
Actuate Therapeutics, Inc (NASDAQ:ACTU) is set to IPO on July 25 on the NASDAQ exchange with shares priced between $8.00 and $10.00. The insider lock-up period will end on January 21, 2025. Actuate Therapeutics is a clinical stage biopharmaceutical company focusing on therapies for difficult-to-treat cancers.
July 24, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actuate Therapeutics, Inc (NASDAQ:ACTU) is set to IPO on July 25 with shares priced between $8.00 and $10.00. The insider lock-up period will end on January 21, 2025. The company focuses on developing therapies for difficult-to-treat cancers.
The IPO of Actuate Therapeutics is likely to generate investor interest due to its focus on high-impact cancer therapies. The pricing range and the insider lock-up period are standard for IPOs, but the company's niche focus could attract significant attention.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100